Patents
Literature
4 results about "Factor V" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Factor V (pronounced factor five) is a protein of the coagulation system, rarely referred to as proaccelerin or labile factor. In contrast to most other coagulation factors, it is not enzymatically active but functions as a cofactor. Deficiency leads to predisposition for hemorrhage, while some mutations (most notably factor V Leiden) predispose for thrombosis.
Therapeutic strategies to reduce thrombotic risk in factor v leiden (FVL) carriers
PCT designated stageWO2026039728A1Immunoglobulins against blood coagulation factorsOrganic active ingredientsThrombusVenous thromboembolism
Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.
Owner:REGENERON PHARMACEUTICALS INC
Human Anti-FV antibody, therapeutic and diagnostic applications thereof
PCT designated stageWO2026022237A1Immunoglobulins against blood coagulation factorsAntibody ingredientsAntiendomysial antibodiesThrombus
The present invention discloses an anti-factor V antibody useful as an anticoagulant agent and as a tool for diagnostic and research applications. The antibody or its fragments can be conveniently used as anticoagulant agents inhibiting Factor V and / or Factor Va, particularly to reduce clot formation and associated thrombotic events, or they can be used in vitro to measure the levels of Factor V in a blood sample. Other aspects of the invention regard nucleic acids encoding the antibody or fragments thereof as well as expression vectors and host cells containing them.
Owner:CEINGE BIOTECNOLOGIE AVANZATE FRANCO SALVATORE SCARL
Therapeutic Strategies To Reduce Thrombotic Risk In Factor V Leiden (FVL) Carriers
PendingUS20260049360A1Immunoglobulins against blood coagulation factorsOrganic active ingredientsThrombusVenous thromboembolism
Methods of reducing the risk of venous thromboembolism (VTE) in a subject undergoing anticoagulant treatment by selectively depleting Factor V Leiden (FVL) in a subject that is heterozygous for FVL, or replacing FVL in the genome of a subject that is homozygous for FVL with a functional Factor V gene, and methods of identifying a subject undergoing anticoagulant treatment who is at risk of developing VTE are disclosed herein.
Owner:REGENERON PHARMACEUTICALS INC
Quantitative method for modified hdl and analytical reagents for the same
Provided is a method for quantifying modified HDL, which is a method for quantifying modified HDL contained in a sample, wherein the modified HDL is allowed to bind to a modified HDL binding protein comprising a protein having the sequence of the L-chain site of factor V or a mutant thereof, and the complex of the modified HDL binding protein and the modified HDL is quantified.
Owner:泽村达也